I am a breastfeeding mother and i want to know if it is safe to use EINECS 264-407-7? Is EINECS 264-407-7 safe for nursing mother and child? Does EINECS 264-407-7 extracts into breast milk? Does EINECS 264-407-7 has any long term or short term side effects on infants? Can EINECS 264-407-7 influence milk supply or can EINECS 264-407-7 decrease milk supply in lactating mothers?
- DrLact safety Score for EINECS 264-407-7 is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of EINECS 264-407-7 may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that EINECS 264-407-7 may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of EINECS 264-407-7 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using EINECS 264-407-7 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
At latest update no published data were found on excretion into breast milk. Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.Its high plasma protein binding capacity makes it highly unlikely a passage into milk.A low oral bioavailability hinders the passage from ingested milk toward the infant’s plasma except in case of premature babies and/or in the immediate neonatal period, in which an increased intestinal permeability may appear. Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.
Because no information is available on the use of EINECS 264-407-7 during breastfeeding, an alternate drug may be preferred.
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.